MNOV News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MN

Mkt Cap

$70.1M

Volume

72.12K

Next Earnings

November 11th

Loading chart

MN

MNOVMedicinova, Inc.

MNOV

Pay with—

Available Balance0.00

MN

Mkt Cap

$69.9M

Volume

72.12K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

MediciNova CEO Provides Shareholder UpdateMediciNova reported topline results from its Phase 2 trial of MN-001 (tipelukast) for nonalcoholic fatty liver disease and hypertriglyceridemia, which did not achieve statistical significance on primary endpoints but showed encouraging signals including significant improvements in HDL cholesterol and early triglyceride reduction. The company also announced completion of patient enrollment in its Phase 2b/3 COMBAT-ALS trial for MN-166 (ibudilast), with topline results expected by year-end.GlobeNewswire Inc. · Oct 12, 2026

MediciNova to Participate in the Maxim Growth SummitMediciNova announced that management will participate in the Maxim Growth Summit on October 12-14, 2026, in New York to meet with investors. The company is developing late-stage clinical programs for inflammatory, fibrotic, and neurodegenerative diseases, with lead asset MN-166 (ibudilast) in trials for ALS, DCM, and MS, and MN-001 (tipelukast) being evaluated for IPF and NAFLD.GlobeNewswire Inc. · Oct 6, 2026

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)MediciNova reported topline results from its Phase 2 MN-001-NATG-202 trial evaluating MN-001 (tipelukast) for treating hypertriglyceridemia and NAFLD in type 2 diabetes patients. The drug showed statistically significant increases in HDL-C and HDL-P, significant early triglyceride reduction at Week 4, and numerical improvements in body weight and liver fat. MN-001 demonstrated a favorable safety profile, though the company indicated a larger study is needed to further evaluate efficacy.GlobeNewswire Inc. · Sep 28, 2026

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightThe alcohol use disorder (AUD) market is projected to grow at a 12.1% CAGR from 2026-2036, driven by novel therapeutic mechanisms and new drug approvals. The market was valued at USD 1.1 billion in 2025 across seven major markets. Key emerging therapies from companies like Adial Pharmaceuticals, Eli Lilly, MediciNova, and Altimmune are expected to transform the treatment landscape, with AD04 projected to capture the largest market share by 2036, replacing current leader VIVITROL.GlobeNewswire Inc. · Jun 8, 2026

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)MediciNova announced the completion of the last patient last visit (LPLV) in its Phase 2 clinical trial (MN-001-NATG-202) evaluating MN-001 (tipelukast) for treating hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes. The randomized, double-blind, placebo-controlled trial enrolled patients receiving either 500 mg/day of MN-001 or placebo for 24 weeks. Top-line data are expected in Q3 2026.GlobeNewswire Inc. · May 26, 2026

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationA peer-reviewed study published in Cancer Research by Spanish National Cancer Research Centre (CNIO) identifies macrophage migration inhibitory factor (MIF)-mediated reprogramming as a central vulnerability in brain metastasis. The research demonstrates that MediciNova's lead compound MN-166 (ibudilast) can effectively block MIF-CD74 signaling and suppress brain metastasis growth in preclinical models. The study also identifies secreted MIF as a potential liquid biopsy biomarker in cerebrospinal fluid, supporting a biomarker-guided clinical strategy. MediciNova plans to collaborate with CNIO on future clinical research for patients with solid tumors having brain metastases.GlobeNewswire Inc. · Apr 27, 2026

MediciNova to Participate at the 38th Annual ROTH ConferenceMediciNova announced that President and CEO Yuichi Iwaki and Chief Business Officer David H. Crean will participate in the 38th Annual ROTH Conference on March 22-24, 2026 in Dana Point, California. The executives will host one-on-one and small group meetings with investors to provide company updates on their clinical-stage biopharmaceutical pipeline.GlobeNewswire Inc. · Mar 16, 2026

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsMediciNova announced that 100 patients have been enrolled in the SEANOBI expanded-access program evaluating MN-166 (ibudilast) for ALS treatment, representing 50% of the planned 200-patient enrollment across 12 US sites. The program is funded by a $22 million NIH/NINDS grant. MN-166 is also being evaluated in the COMBAT-ALS Phase 2b/3 trial with 234 patients enrolled, with top-line results expected by end of 2026.GlobeNewswire Inc. · Jan 29, 2026

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MNDMediciNova completed randomization of 234 patients in its COMBAT-ALS clinical trial for MN-166, a potential treatment for Amyotrophic Lateral Sclerosis. The company anticipates top-line data by end of 2026 and remains hopeful about the drug's therapeutic potential.GlobeNewswire Inc. · Dec 8, 2025

Message from the CEO to MediciNova ShareholdersMediciNova published research demonstrating how its drug MN-001 potentially improves cholesterol transport and addresses metabolic disorders, with Phase 2 trial results expected in summer 2026.GlobeNewswire Inc. · Dec 1, 2025

to start trading

MN

MNOVMedicinova, Inc.

MNOV

Pay with—

Available Balance0.00

Your PositionYou don't own any MNOV yet.

Related Tickers

Earnings